A small team with one goal: to rewrite the script on genetic disorders, with deep expertise across neuroscience, computational biology, and gene-editing R&D.
Led by experts in gene editing, AI, and pharma, Neoclease is driven by precision.
Founded Neoclease in 2023 to build gene-specific editors, starting with Parkinson's. Neuroscience PhD from Boston University, with research in translational neuroscience and preclinical disease models. Previously led external partnerships across global clinical development at Regeneron, and ran business development at Empatica, closing and managing deals with Top 10 pharma, BARDA, NASA, and the U.S. Army.
Ph.D. in Computational Chemistry (Ohio State), with postdoctoral training at NCI-Frederick, NIH. Tenured professor at UNTHSC running a lab focused on synthetic biology, AI, and genetic engineering, with deep expertise in molecular dynamics and nuclease specificity.
Research & Publications →
Over a decade at the forefront of gene editing across Harvard Medical School, Boston University School of Medicine, and seven-plus years at CRISPR Therapeutics leading in vivo editing R&D, including work contributing to the first FDA-approved gene editing therapy. Has led R&D programs through to IND.
20+ years building companies and scaling technology and software startups, bringing the operational discipline to turn Neoclease's platform into a repeatable, partner-ready business.
AI/ML expert building generative models, transformer architectures, and deep learning systems, the machinery that designs and screens Neoclease's gene-specific editors.